Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge Included in International Business Deal
Mandate

Vinge Included in International Business Deal

February 11, 2008

Vinge advises EQT on transfer of the Finnish Finn-Power Group to Prima Industries, listed in Italy. The transfer was resolved according to UK law. By the acquisition of the
Finn-Power Group Prima Industries will reach 50 countries which in turn will make Prima Industries the third largest producer of laser machines in the world. The group’s annual revenues are calculated to reach an estimated value of EUR 400 million.    

Cleary Gottlieb Steen & Hamilton represented the buyer and the Italian law firm Tosetto Weigmann e Associati handled the financing. Clifford Chance represented the Italian banks that financed the transfer and in addition to this assistance also came from the Finnish law firms Roschier, Hannes Snellman and Castrén & Snellman.   
 
Vinge’s team was co-ordinated by Anders Åberg and Tuula Tallavaara joined by James Hope, Petter Kjöllerström and Jenny Henriksson.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026